跳到正文
原文
STAT 主站· Jason Mast and O. Rose Broderick·· 2 小时前AI 评分35

研究探索 CTE 血液检测可能性

Researchers explore possibility of a CTE blood test

AI 导读

研究者发表数据表明,通过分析血液中的特定形式tau蛋白,可能在未来开发出诊断慢性创伤性脑病(CTE)的血液检测方法。该研究涉及18名已通过脑 autopsy 确诊 CTE 的足球运动员,结果显示血液中特定形式的 tau 蛋白水平升高,且病情越严重,血液中该蛋白水平越高。研究者表示,这标志着诊断 CTE 的重大进展,但仍需进一步验证。

正文

Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here.

Good morning, everyone. Are you a fan of “Grand Theft Auto”? Will your boss not give you the day off to play the video game you’ve been waiting 13 years for? Don’t worry, DJ Khaled and Dr. Xbox have you covered. Just click here and fill out the form. You’ll have a diagnosis and doctor’s note for Vitamin G deficiency faster than a telehealth company can prescribe you a peptide.

Which, speaking of …

Peptides go mainstream

Unapproved and off-label peptide drugs have long been popular with bodybuilders looking for an edge, but they could soon become a mass market health product, thanks to new initiatives from two popular telehealth companies.

Hims & Hers unveiled Thursday its Peptides+ program, offering two peptides alongside several compounded medications popular among peptide users. Noom announced its own offerings this week as well. This follows a decision by FDA leaders to — despite the concerns of staff scientists – allow compounders to produce six peptides that haven’t been approved by the agency, including BPC-157 and TB-500. Hims said it will soon offer BPC-157 and TB-500; Noom is considering adding them too.

Telehealth companies argue their peptides will be safer and more reliable than the black market “research-grade” products often used today, and Hims notes its program will offer twice-yearly blood tests for patient monitoring. But critics contend selling drugs that haven’t gone through the FDA’s approval process for their proposed use will bring products that have not been proven safe or effective to many patients who would not have otherwise encountered them.

Read more from Sarah and Katie.

U.S. drugmakers pull back from (parts of) China

A few of the largest U.S. drugmakers recently told a Congressional committee they would not start new clinical trials in the Xinjiang region of China or in hospitals affiliated with the Chinese military.

The concessions come as U.S. pharmas rush to partner with Chinese biotech startups and hospitals, alarming some American lawmakers. Last year, the House Select Committee on China opened investigations into Merck, Eli Lilly, AbbVie, Pfizer, and Bristol Myers Squibb over concerns about intellectual property exposure, military entanglements, and ethical standards at trial sites. All five of those companies have now agreed to not start any new trials at hospitals with ties to the People’s Liberation Army.

Four — all but AbbVie — agreed to stop trials in Xinjiang, where the Chinese government has targeted Uyghurs and other ethnic and religious minorities. AbbVie cited a “duty to provide potentially lifesaving treatment to patients there, most of whom company officials stated are oncology patients in a critical state of disease,” according to the committee, which is releasing a report today about its findings.

12 weeks

That’s how long journals should generally take to review potentially problematic studies, according to a report from the National Academies of Sciences, Engineering, and Medicine. 

The 157-page document comes after a raft of papers from high-profile scientists at places like Stanford University and the Dana-Farber Cancer Institute were alleged to contain doctored data, contributing to distrust in scientific institutions. The authors found that allegations don’t always lead to retractions, even when they should. They encouraged journals to be more aggressive in retracting studies, and urged editors to review concerns raised within four weeks. Researchers, in turn, should not argue a study should remain up because errors in one section don’t impact the overall findings.

The National Academies’ report was supposed to be released publicly Thursday morning. But as of Thursday evening, it had not been published on the nonprofit’s website, though advanced copies were sent to media outlets. Jennifer Walsh, a National Academies spokesperson, told STAT in an email that “the report is being paused pending further review of some of the citations.” She did not provide a new release time. Reporting by Science alleges that 10 of the report’s references contain apparently fabricated first names for co-authors, suggesting that a large language model may have written the references.

Read more.

A blood test for CTE?

Neurologists trying to treat or prevent CTE, the degenerative brain disease caused by repeated blows to the head, have long been hampered by the fact that the disease can only be diagnosed after death, with an autopsy. But on Thursday, researchers published data that could one day lead to a CTE blood test.

The key was 21 football players who donated blood while they were alive and then gave their brains to the Boston University CTE Center Brain Bank after death. Eighteen had confirmed CTE, by autopsy; among those 16 had advanced disease. Researchers found a particular form of tau — the toxic protein tangles that build up in the brains of patients with CTE and other neurodegenerative disorders — was elevated in those 18 volunteers’ blood, relative to those who didn’t have CTE. And subjects with advanced CTE had higher blood levels of this form of tau, called eMTBR-tau, than those with mild CTE.

“While there is still much work to do to validate these findings before the test is ready to use in patients, I am very hopeful that this study marks a major milestone in our ability to diagnose and ultimately treat this devastating disease,” co-author Gil Rabinovici Edward at the University of California San Francisco said in a statement.

Senators recommend new NIH disability research office

The National Institutes of Health may soon have an office dedicated to disability health research.

The Senate Appropriations Committee’s budget recommendations for the next fiscal year, released Wednesday, urge the NIH to establish a “centralized disability research office” and fulfill the agenda laid out in the agency’s strategic plan for this health disparity group.

If the office is created, it will have a tall task on its hands. More than a quarter of Americans have a disability, but many are routinely excluded from clinical trials. Take dementia and Alzheimer’s research. The federal government now spends $3.9 billion annually on dementia research, but clinical trials for Alzheimer’s therapeutics have excluded people with Down syndrome for decades, even though 90% of people with Down syndrome will develop Alzheimer’s by the age of 55.

The budget is not a one-to-one reflection of Congress’s budget next year, so there’s no guarantee that this office will be created. But advocates cheered the inclusion on social media. – O. Rose Broderick

What we’re reading

  • Anthropic IPO: 4 ways the AI giant wants to disrupt science, Nature

  • Marsha Linehan has died. She transformed treatment for personality disorder, New York Times
  • Eighth measles death reported as Pennsylvania nears 1,600 cases, Washington Post
  • Gig work is invading nursing homes. The risks can be deadly, Proof News
  • Study raises doubts about combining vaccine, monoclonal antibody to protect against malaria, STAT

来源:STAT 主站 · statnews.com